The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Reuben Dawkins, CEO of Link Biologics, a company developing protein biologics to treat inflammatory and degenerative conditions. Link is currently developing treatments for Dry Eye… Read More
Darren Heywood, Senior Product Manager at Promega UK, examines assay formats built specifically for 3D measurements. A 3D microtissue, such as a spheroid or organoid, is not a monolayer with more cells. These are three-dimensional… Read More
Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology. Every… Read More
Partha Anbil, SVP, Life Sciences, at Coforge Limited, and Alex Kandybin, Founder of Quantum Wargaming, explore how quantum computing is… Read More
With the largest diabetic population and a pedigree in metabolic diseases, China is becoming one to watch in diabetes and obesity drug discovery. Diana Turner finds out about an increasingly competitive market. Research by clinical research organisation ICON in late… Read More
Yan Zhang, President of proteomic sciences at Thermo Fisher Scientific, writes about developments in precision medicine and how biobanks are key to … Read More
DNA Script has announced a distribution agreement with Imperial Life Sciences (ILS) to expand access to the company’s DNA synthesis platform. The partnership will mean DNA Script’s SYNTAX platform will now be available in India. Under the agreement, ILS will distribute DNA Script’s SYNTAX platform throughout the country,… Read More
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to a treatment for metastatic hormone-sensitive prostate cancer (mHSPC). Akeega (niraparib and abiraterone acetate), developed by Johnson & Johnson, has been granted the authorisation as part of a combination regimen with prednisone or prednisolone and andogren deprivation therapy (ADT). … Read More
We’re delighted to announce Chris Molloy, Chief Executive Officer of the UK BioIndustry Association (BIA), as keynote speaker at Drug Discovery Innovators & Investors, London, UK Conference. The conference theme, Technology, Speed, Scale, and Capital: Advancing UK Drug Discovery and Development, will bring together senior executives, R&D leaders, lab managers… Read More
A new drug that reduces heart muscle thickening could represent a new treatment option for heart disease patients, a study says. The TEMPEST trial, led by researchers at the University of Manchester, tested the drug trientine in 154 adults with hypertrophic cardiomyopathy in a year-long, placebo-controlled study. Read More
Steven Bulera, Corporate Vice President, Chief Scientific Officer: Safety Assessment, Charles River Laboratories, explores various use-cases of AI in improving drug discovery. It’s difficult, if not impossible, to escape the headlines and… Read More
mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say. Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted… Read More
In March 2026, Lineage Cell Therapeutics launched a new cell therapy programme for the treatment of corneal endothelial disease. Diana Turner caught up with Brian Culley, CEO of Lineage Cell Therapeutics… Read More
Camena Bioscience has appointed Gregory McGuinness as CEO as it looks to scale its antibody discovery platform. The biotechnology company, which sees itself as a pioneer in enzymatic DNA synthesis for AI-driven antibody discovery, has appointed McGuinness to support the company’s growth, including its commercialisation of AI-driven antibody… Read More
Evonik has announced a partnership with global antibody expression specialist evitria as it looks to accelerate its early biologics development. The collaboration is set to advance a transient protein expression kit based on CHO cells for biopharmaceutical research and development. Evonik says the kit is designed to enable… Read More
Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it. Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More
